Compare Gilead Sciences, Inc. (GILD) vs Hewlett Packard Enterprise Co (HPE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Hewlett Packard Enterprise Co — how do they compare? Gilead Sciences, Inc. trades at $149.66 (market cap $182.40B), while Hewlett Packard Enterprise Co trades at $71.27 (market cap $94.25B). The key difference: Gilead Sciences, Inc. is the larger of the two by market cap, and Gilead Sciences, Inc. pays the higher dividend (2.23%). Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Hewlett Packard Enterprise Co for 33 Days on average.
| GILD | HPE | |
|---|---|---|
Market Cap | $182.40B | $94.25B |
Volume | 4,469,821 | 16,060,854 |
Sector | Health | Technology |
52-Week High | $155.80 | $72.12 |
52-Week Low | $116.74 | $20.01 |
Typical Hold Time | 111 Days | 33 Days |
Enterprise Value | $205.46B | $108.28B |
Dividend Yield | 2.23% | 0.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% today, with a bullish technical signal from moving averages and recent earnings beats in Q4 2025 and Q1 2026. The company reported strong 2025 revenue of $29.44B and net income of $8.51B, though 2026 projections show a net loss. Key developments include a partnership with PAHO to expand HIV prevention drug access in Latin America, supporting long-term growth prospects amid mixed profitability metrics.
The outlook for GILD is cautiously optimistic, driven by analyst consensus favoring a buy rating (65.52%) and a price target of $151.57. Opportunities lie in HIV and oncology pipeline advancements, but risks include negative 2026 profit margins and high debt levels. Investors should weigh strong cash flow from operations against execution risks in a competitive biopharma landscape.
HPE's stock is trading at $72.12, up 2.2% today and near its all-time high, driven by strong AI infrastructure demand. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of $1.11 surpassing the $0.932 estimate. The company secured a $1.2 billion AI server order from Vultr and raised its networking outlook, fueling bullish technical signals and positive analyst sentiment.
The outlook remains optimistic due to AI-driven growth and raised revenue targets, but risks include high valuation multiples and volatile cash flows. With a consensus price target of $70.35, slightly below the current price, the stock faces potential near-term resistance despite strong fundamentals and institutional upgrades.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Hewlett Packard Enterprise Co
Hewlett Packard Enterprise is an information technology vendor that provides hardware and software to enterprises. Its primary product lines are compute servers, storage arrays, and networking equipment.
Read more on HPE →
